Nadroparin (Ca)
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Nadroparin (Ca) is a low molecular weight heparin with anti-coagulant properties. Nadroparin (Ca) is used in the treatment and prophylaxis of venous thrombo-embolism and to prevent clotting during extracorporeal circulation.
Indications
Nadroparin (Ca) is primarily indicated in conditions like Prophylaxis of thrombosis, Pulmonary embolism, Thromboembolism, and can also be given in adjunctive therapy as an alternative drug of choice in Unstable angina.
Contraindications
Nadroparin (Ca) is contraindicated in conditions like Diabetic retinopathy, Severe uncontrolled hypertension, Hypersensitivity to any component of product.
Side Effects
The signs and symptoms that are produced after the acute overdosage of Nadroparin (Ca) include Hemorrhage. The symptomatic adverse reactions produced by Nadroparin (Ca) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Rashes, Allergic reactions, Thrombocytopenia, Bleeding, Pain at injection site, Hypoaldosteronism, Injection site hematoma.
Warnings
Patients with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) are at risk of spinal or epidural hematoma and subsequent paralysis. Patient should be closely monitored for signs or symptoms of bleeding. Should be use with caution in patients with severe hepatic or renal disease. Safety and efficacy in pediatric patients have not been established. Should not be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.
High Risk Groups
Drug should not be given to Paediatrics, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
250 mg (250 (250)) 12 hourly PO —
Child Dosage
( ) — Not recommended in this age group
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
No data regarding the interactions of Nadroparin (Ca) was found.
Storage
Inj Store Between 15°C-30°C. Refrigeration and Freezing is not recommended.
Available Brands in Pakistan
No active brands are currently recorded for this generic.
1 record is present but flagged "Unverified / Legacy" and excluded.